ResMed (RMD) Misses Q3 EPS by 10c
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $194.78 +1.24%
EPS Growth %: +13.3%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +13.3%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q3 EPS of $1.32, $0.10 worse than the analyst estimate of $1.42. Revenue for the quarter came in at $864.5 million versus the consensus estimate of $897.04 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- The Lovesac Company (LOVE) Tops Q1 EPS by 29c
- BIG3 Basketball to go public via Graf Global merger at $290 million
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
